CHEPLAPHARM Arzneimittel GmbH


This section provides relevant information as well as ongoing and timely updates on the strategic and operative success stories of our steadily growing Company.


Your contact persons

Jens Remmers

Head of Treasury & Investor Relations

IR center of information

Financial Reports

02nd June 2022
Investor Call Quarterly Report Q1 2022
31st May 2022
Publication Quarterly Report Q1 2022
10th May 2022
Investor Call Full Financial Year 2021 audited
29th April 2022
Publication Full Financial Year 2021 audited
30th November 2021
Investor Call Quarterly Report Q3 2021
19th November 2021
Publication Quarterly Report Q3 2021
24th August 2021
Investor Call Quarterly Report Q2 2021
20th August 2021
Publication Quarterly Report Q2 2021
Find out how you can benefit


The latest from CHEPLAPHARM



CHEPLAPHARM acquires product package from Bristol-Myers Squibb – significant expansion of our portfolio

CHEPLAPHARM Arzneimittel GmbH continues its successful expansion strategy by purchasing three further global niche products.

more chevron_right


CHEPLAPHARM acquires global rights to Questran® from Bristol-Myers Squibb

CHEPLAPHARM Arzneimittel GmbH continues with its diversification strategy.

more chevron_right


CHEPLAPHARM acquires product rights for ATACAND® and ATACAND® Plus from AstraZeneca in Europe

CHEPLAPHARM is pleased to announce the acquisition of the commercial rights to ATACAND® (Candesartan Cilexetil) and ATACAND® Plus (fixed-dose combination of Candesartan Cilexetil and…

more chevron_right


CHEPLAPHARM invests 6 million euros in the expansion of its German headquarters in Greifswald – funded by own sources only

From August 2018, CHEPLAPHARM expands its Ziegelhof headquarters in the Hanseatic city of Greifswald with a new building on an area of 5,300 square meters. The extension with state-of-the-art office…

more chevron_right
Investor Relations Archive


CHEPLAPHARM’s successful Capital Markets debut: 780 million euros new lending facilities agreed and thus future financing sources secured

CHPLAPHARM Arzneimittel GmbH has successfully completed the refinancing of existing loans and promissory notes.

more chevron_right


CHEPLAPHARM steps into Therapeutic Area on a large-scale

By acquiring the worldwide rights (except US) for the product VISUDYNE® from the Swiss Novartis Pharma AG, CHEPLAPHARM is now active in the Therapeutic Area Ophthalmology (AMD – age-related macular…

more chevron_right


CHEPLAPHARM receives credit ratings: A premiere for a medium-sized company in Mecklenburg-Western Pomerania

In the course of an external credit rating, CHEPLAPHARM is rated B/B1 - and thus stable future outlooks.

more chevron_right


CHEPLAPHARM further enhances its portfolio in the Cardiology area

CHEPLAPHARM Arzneimittel GmbH is pleased to announce that we have signed definitive agreements with Bristol-Myers Squibb to acquire product SOTALEX®.

more chevron_right


CHEPLAPHARM continues its expansion course and complements its portfolio with four further products

Right at the beginning of the year, the fast-growing pharmaceutical company CHEPLAPHARM Arzneimittel GmbH secures the product rights for CYMEVENE®, KONAKION®, LARIAM® and INHIBACE®/Plus from F.…

more chevron_right


CHEPLAPHARM engaged DKSH to market its regional business in several Asian countries

Zurich (CH) / Greifswald (DE), December 15, 2017 – In a formal ceremony at the DKSH headquarters in Zurich, DKSH and CHEPLAPHARM Arzneimittel GmbH have signed a strategic partnership for a regional…

more chevron_right

Investor Relations topics

Back to top expand_less